Affiliation:
1. Ankara Bilkent City Hospital
Abstract
Abstract
Background: Axitinib is a selective inhibitor of vascular endothelial growth factor receptors.
Case presentation: A forty-five years old female presented with blurred vision who had been taking 7 mg of Axitinib bid for 5 months. Initial best corrected visual acuity (BCVA) was 20/32 at the right and counting fingers at the left eye. Funduscopic examination revealed bilaterally widespread intraretinal hemorrhages, cotton-wool spots, and hard exudates with a star-like appearance at the macula. The optical coherence tomography revealed central macular edema. There was hyperreflective edema in the inner layers, exudates in the middle retinal layers and subfoveal subretinal fluid. Fundus fluorescein angiography revealed localized ischaemic findings in the early phase and multifocal perivascular ink-blot fluorescein leakage in the middle and late phases.
Conclusions: Axitinib treatment was discontinued immediately, and at the 3-month of follow-up, the macular edema and fundus findings improved with final BCVA 20/20 at the right, and 20/32 at the left eye.
Publisher
Research Square Platform LLC
Reference10 articles.
1. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitör of vascular endothelial growth factor receptor tyrozine kinases 1,2,3;Hu-Lowe DD;Clin Cancer Res,2008
2. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):randomised phase 3 trial;Rini BI;Lancet,2011
3. A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma;Gross-Gupil M;Clin Med Insights Oncol,2013
4. Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis;Wang H;Onco Targets and Therapy
5. Reversible retinal toxicity in a patient taking axitinib;Jenkins TL;Retinal Cases Brief Reports,2018